Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Operating Expenses (2021 - 2025)

InMed Pharmaceuticals' Other Operating Expenses history spans 5 years, with the latest figure at $35065.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 60.49% year-over-year to $35065.0; the TTM value through Dec 2025 reached $225938.0, down 6.1%, while the annual FY2025 figure was $191106.0, 24.69% up from the prior year.
  • Other Operating Expenses reached $35065.0 in Q4 2025 per INM's latest filing, down from $110196.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $145839.0 in Q3 2022 to a low of -$8.8 million in Q2 2022.
  • Average Other Operating Expenses over 5 years is -$868019.1, with a median of $31798.5 recorded in 2021.
  • The largest YoY upside for Other Operating Expenses was 448.39% in 2024 against a maximum downside of 75.76% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at -$4.2 million in 2021, then surged by 99.45% to -$23286.0 in 2022, then dropped by 24.71% to -$29040.0 in 2023, then soared by 405.6% to $88746.0 in 2024, then plummeted by 60.49% to $35065.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Other Operating Expenses are $35065.0 (Q4 2025), $110196.0 (Q3 2025), and $18409.0 (Q2 2025).